Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee

NCT00819572 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis

Interventions

BIOLOGICAL: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
DRUG: Placebo

Sponsor

ESBATech AG